WHO publishes list of essential diagnostic tests
FDA addresses variant databases and germline tests
In what is viewed as a step forward for NGS-based clinical testing, the US Centers for Medicare & Medicaid Services (CMS) announced this month a final National Coverage Determination (NCD) for FDA-approved NGS tests for advanced cancer (defined as either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV) patients as long as certain […]
New fee schedule brings significant cuts to clinical labs
NGS and array-based testing for pre-implantation genetic screening
New players enter the fast-growing CDx market
New multiplex technology scheduled to launch later this year
FDA establishes new pathway for cancer LDTs
Pennsylvania-based organization provides clinical genetic sequencing screening for patients
Agilent and BD launch new products
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.